Overview

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

Status:
Terminated

Trial end date:
2020-06-09

Target enrollment:

Participant gender:

Summary

This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either refuse or are ineligible for intensive therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Yale University

Collaborators:

Pfizer
Pfizer Inc., U.S. Pharmaceuticals Group

Treatments:

Decitabine